Brain

NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)

ZURICH, SWITZERLAND / ACCESSWIRE / June 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage…

1 day ago

ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY

AGOURA HILLS, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu…

1 day ago

Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001

With Growing Body of Clinical Evidence, ALX-001 is Ready to Commence Phase 2 StudiesNEW HAVEN, Conn., June 11, 2024 (GLOBE…

1 day ago

TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients

Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical…

1 day ago

Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer’s Patients

Join Our Investor Call for In-Depth Findings Discussion Efficacy in Early AD Patients Buntanetap showed statistically significant efficacy and safety…

1 day ago

IRLAB Participates in Stora Aktiedagarna

GOTHENBURG, SWEDEN / ACCESSWIRE / June 11, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, June 11, 2024 - IRLAB Therapeutics…

2 days ago

Cala TAPS Therapy is Now Covered by Medicare for Essential Tremor Patients, And Company Appoints CEO and President

SAN MATEO, Calif., June 10, 2024 /PRNewswire/ -- Cala, the bioelectronic medicine leader, reached a major milestone: a positive Medicare…

2 days ago

Galimedix Therapeutics Establishes Scientific Advisory Board of Renowned Retina Experts as Company Prepares to Enter Phase 2 Clinical Study with GAL-101

Board consists of key opinion leaders from both clinical practice and academia with strong track records in the development of…

2 days ago

Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona

June 10, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial…

2 days ago

Presentation at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2024 Annual Meeting Highlights Ashvattha Product Candidates for Neuroinflammation Imaging and Treatment

Preclinical data highlights the therapeutic potential of Ashvattha’s novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based…

2 days ago